SG11201810332TA - Neoepitope vaccine compositions and methods of use thereof - Google Patents

Neoepitope vaccine compositions and methods of use thereof

Info

Publication number
SG11201810332TA
SG11201810332TA SG11201810332TA SG11201810332TA SG11201810332TA SG 11201810332T A SG11201810332T A SG 11201810332TA SG 11201810332T A SG11201810332T A SG 11201810332TA SG 11201810332T A SG11201810332T A SG 11201810332TA SG 11201810332T A SG11201810332T A SG 11201810332TA
Authority
SG
Singapore
Prior art keywords
international
neo
methods
jefferson
boulevard
Prior art date
Application number
SG11201810332TA
Inventor
Frank Jones
Adrian Rice
Patrick Soon-Shiong
Kayvan Niazi
Shahrooz Rabizadeh
Original Assignee
Etubics Corp
Nant Holdings Ip Llc
Nantcell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etubics Corp, Nant Holdings Ip Llc, Nantcell Inc filed Critical Etubics Corp
Publication of SG11201810332TA publication Critical patent/SG11201810332TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001161—Caspases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION ,,,,,,,,,1111.111.„ m„ Organization 11„ ,,,,,,„„,11,11„,,,,,,,,,,,,,111111111111111111111101111 (19) World Intellectual Property ---,. International Bureau (10) International Publication Number (43) International Publication Date ...../ WO 2017/205810 A8 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: SOON-SHIONG, Patrick; 9920 Jefferson Boulevard, Cul- A61K 39/00 (2006.01) C07K 14/705 (2006.01) ver City, CA 90232 (US). NIAZI, Kayvan; 9920 Jefferson C12N 15/86 (2006.01) Boulevard, Culver City, CA 90232 (US). RABIZADEH, (21) International Application Number: Shahrooz; 9920 Jefferson Boulevard, Culver City, CA PCT/US2017/034802 90232 (US). (22) International Filing Date: (74) Agent: RAMANATHAN, Renuka et al.; Wilson Sonsini 26 May 2017 (26.05.2017) Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/342,752 27 May 2016 (27.05.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicants: ETUBICS CORPORATION [US/US]; 410 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, West Harrison Street, Suite 200, Seattle, WA 98119 (US). KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, NANT HOLDINGS IP, LLC [US/US]; 9922 Jefferson MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, Boulevard, Culver City, CA 90232 (US). NANTCELL, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, INC. [US/US]; 9920 Jefferson Boulevard, Culver City, CA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = 90232 (US). TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: JONES, Frank, R.; 410 West Harrison Street, (84) Designated States (unless otherwise indicated, for every = Suite 200, Seattle, WA 98119 (US). RICE, Adrian; 410 kind of regional protection available): ARIPO (BW, GH, — West Harrison Street, Suite 200, Seattle, WA 98119 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = — (54) Title: NEOEPITOPE VACCINE COMPOSITIONS AND METHODS OF USE THEREOF (57) : In certain embodiments, methods and compositions are pro- _ _ = Patient Sample —* Whole exome sequencing for mutations vided for generating immune responses against tumor neo-antigens or neo- epitopes. In particular embodiments there may be provided methods for con- = strutting and producing recombinant adenovirus-based vector vaccines con- taining nucleic acid sequences encoding tumor neo-antigens and neo-epitopes = — — - = =f - Translation of mutated sequence with centrally positioned (and corresponding WT peptide) mutant into 17mer amino acid that allow for vaccinations in individuals with preexisting immunity to aden- ovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant ade- killer cells. In = MHC Class I prediction novirus-based vectors combined with engineered natural some binding Analysis embodiments, the methods and compositions further comprises a nucleic acid — encoding for an immunological fusion partner. = — = IEBD Analysis homology to known epitopes from of or cancers i T cell interaction prediction (IEBD program) GC Peptides predicted to bind MHC Class I with IC505500 (- Peptides predicted toy bind MHC Class I with 1050.500 , or interact with T cell, © 11 GC kr) © Candidate Neo-antlgens or Neo-epltopes r'l --.... IN FIG. 1 1-1 0 r'l C [Continued on next page] WO 2017/205810 A8 MIDEDIMOMOIDEIROIDEMODIMINHOMMOVE# UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (48) Date of publication of this corrected version: 04 January 2018 (04.01.2018) (15) Information about Correction: see Notice of 04 January 2018 (04.01.2018)
SG11201810332TA 2016-05-27 2017-05-26 Neoepitope vaccine compositions and methods of use thereof SG11201810332TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342752P 2016-05-27 2016-05-27
PCT/US2017/034802 WO2017205810A1 (en) 2016-05-27 2017-05-26 Neoepitope vaccine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201810332TA true SG11201810332TA (en) 2018-12-28

Family

ID=60411886

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810332TA SG11201810332TA (en) 2016-05-27 2017-05-26 Neoepitope vaccine compositions and methods of use thereof

Country Status (11)

Country Link
US (2) US20200282032A1 (en)
EP (2) EP3463440A4 (en)
JP (2) JP2019517577A (en)
KR (2) KR20190034504A (en)
CN (1) CN109890408A (en)
AU (1) AU2017268822B2 (en)
CA (1) CA3025648A1 (en)
IL (1) IL263287A (en)
MX (1) MX2018014602A (en)
SG (1) SG11201810332TA (en)
WO (1) WO2017205810A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811074RA (en) 2016-06-30 2019-01-30 Nant Holdings Ip Llc Nant cancer vaccine
WO2018089637A1 (en) * 2016-11-11 2018-05-17 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
US11932676B2 (en) * 2016-11-22 2024-03-19 Klotho Therapeutics, Inc. Recombinant klotho proteins and compositions and methods involving same
KR20190110612A (en) 2017-02-01 2019-09-30 모더나티엑스, 인크. Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
BR112019024127A2 (en) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. TARGETED IMMUNOTOLERANCE
AU2018275147B2 (en) * 2017-06-02 2021-01-28 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019147925A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
WO2019191100A1 (en) 2018-03-26 2019-10-03 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
TWI816603B (en) * 2018-04-23 2023-09-21 美商南特細胞公司 Neoepitope vaccine and immune stimulant combinations and methods
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
US20210230548A1 (en) * 2018-05-03 2021-07-29 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
US20200087680A1 (en) * 2018-09-13 2020-03-19 Nantbio, Inc. Conditional Living Sensors
CN113677328A (en) * 2019-01-09 2021-11-19 埃克索丘尔生物科学股份有限公司 Vesicles of bacterial origin and uses thereof
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
KR20220035333A (en) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 MADCAM Targeted Immune Tolerance
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
WO2021091541A1 (en) * 2019-11-05 2021-05-14 Kri Technologies Incorporated Identifying cancer neoantigens for personalized cancer immunotherapy
WO2021186278A1 (en) * 2020-03-20 2021-09-23 Immunitybio, Inc. T cells that respond to patient neoepitopes
US11920202B2 (en) * 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
WO2022086727A1 (en) * 2020-10-19 2022-04-28 Nantbio, Inc. Arrayed peptide neoepitope generator
CN113667001B (en) * 2021-03-24 2023-03-31 深圳市新靶向生物科技有限公司 Antigenic peptide related to lung cancer driver gene mutation and application thereof
WO2023196936A1 (en) * 2022-04-06 2023-10-12 Imunon, Inc. Polynucleotide cancer vaccine compositions and methods of using the same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600820A (en) 1898-03-15 Registering voting-machine
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
DK0641192T3 (en) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Transmucosal drug delivery device
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
CO4600681A1 (en) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma PHARMACEUTICAL COMPOSITION FOR IMMUNITY MODULATION
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US20060269532A1 (en) * 1997-02-25 2006-11-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
CA2678259C (en) * 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
JP2004513615A (en) * 2000-06-28 2004-05-13 コリクサ　コーポレイション Compositions and methods for treatment and diagnosis of lung cancer
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
JP2006506072A (en) * 2002-11-12 2006-02-23 デイッセロース，アルバート，ビー Adenovirus vector vaccine
US20040202648A1 (en) * 2003-04-04 2004-10-14 Cabezon Teresa Elisa Virgina Silva Vaccines
WO2008012237A1 (en) * 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
HRP20211595T1 (en) * 2011-05-24 2022-01-21 BioNTech SE Individualized vaccines for cancer
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
EP3912637A1 (en) 2014-06-30 2021-11-24 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
US20190091316A1 (en) * 2016-02-11 2019-03-28 Nant Holdings Ip, Llc Subcutaneous Delivery of Adenovirus with Dual Targeting

Also Published As

Publication number Publication date
JP2020169177A (en) 2020-10-15
US20210138056A1 (en) 2021-05-13
KR20190034504A (en) 2019-04-02
EP3463440A1 (en) 2019-04-10
AU2017268822B2 (en) 2020-03-26
MX2018014602A (en) 2019-06-10
JP2019517577A (en) 2019-06-24
US20200282032A1 (en) 2020-09-10
WO2017205810A8 (en) 2018-01-04
IL263287A (en) 2018-12-31
CA3025648A1 (en) 2017-11-30
AU2017268822A1 (en) 2018-12-13
EP3463440A4 (en) 2020-04-15
CN109890408A (en) 2019-06-14
KR20200138418A (en) 2020-12-09
WO2017205810A1 (en) 2017-11-30
EP3735984A1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
SG11201810332TA (en) Neoepitope vaccine compositions and methods of use thereof
SG11201808196UA (en) Neoantigens and methods of their use
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201810591VA (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201901979SA (en) Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201807300PA (en) Uterine cancer treatments
SG11201804969PA (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201808797XA (en) T cell receptors
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201810631SA (en) Compositions and methods for tumor vaccination using prostate cancer-associated antigens
SG11201806398YA (en) Optimized factor viii genes